Assessment of myocardial perfusion in patients with hypertrophic cardiomyopathy in comparison with clinical and echocardiographic data

Cite item

Full Text


Aim. To study peculiarities of myocardial perfusion in patients with hypertrophic cardiomyopathy (HCMP) in correlation with clinical and echocardiographic data.
Material and methods. 62 patients with HCMP (23 females and 39 males, mean age 44.4 ± 11.2 years, the disease duration 13.0 + 10.4 years) have undergone ECG, 24-h ECG monitoring, echocardiography, perfusion scintigraphy of the myocardium with 99m-TcMIBI at rest and in combination with bicycle ergometry. The patients were divided into two groups: 35 patients of group 1 had moderate left ventricular hypertrophy (the septal thickness in diastole under 20 mm; 27 patients of group 2 had severe hypertrophy (the tickness was over 20 mm).
Results. Dyspnea and syncopal states occurred more frequently in patients from group 2. They also had a higher functional class of heart failure (2.0 ± 0.8 and 1.2 ± 0.7 for group 1 and 2, respectively, p < 0.05). Cardiac performance was significantly higher in patients of group 1. The size of the left atrium, left ventricular myocardium mass, the septal thickness and thickness of posterior wall of the left ventricle, gradient of pressure in the outflow tract of the left ventricle proved higher in patients of group 2. Deep stable defects of myocardial perfusion were detected in 5 (15%) patients of group 1 and 10 (37%) patients of group 2. Transient defects of myocardial perfusion were found in 9 (26%) patients of group 1 and 12 (44%) patients of group 2. The index of myocardial ischemia in group 1 patients was significantly lower than in patients of group 2 (3.5 + 2.2 and 8.3 ± 2.5, respectively, p < 0.05).
Conclusion. Patients with severe hypertrophy of the left ventricle had severe clinical picture, low exercise tolerance, marked hemodynamic changes, more frequent defects of left ventricular perfusion defects compared to patients with moderate hypertrophy of the left ventricular myocardium.


  1. Магоп В. J., Epstein S. Е., Roberts W. С. et al. Hypertrophic cardiomyopathy and transmural myocardial infarction without significant atherosclerosis of the coronary arteries. Am. J. Cardiol. 1979; 43: 1086.
  2. Tanaka M., Fujinara H., Onodera T. et al. Qualitative analysis of myocardial fibrosis in normals. Hypertensive hearts and hypertrophic cardiomyopathy. Br. Heart J. 1986; 55: 575.
  3. McKenna W. J., Deanfield J., Faruqui A. et al. Prognosis in hypertrophic cardiomyopathy. Role of age and clinical, electrocardiographic and hemodynamic features. Am. J. Cardiol. 1981;47:532-538.
  4. Maron B. J., Wolfson J. K., Roberts W. С. et al. Relation between extent of cardiac muscle cell disorganisation and left ventricular wall thickness in hypertrophic cardiomyopathy. Ibid. 1992; 15: 785-790.
  5. Cannon R. O., Rosing D. R., Maron B. J. et al. Myocardial ishemia in patients with hypertrophic cardiomyopathy contribution of inadequate vasodilator reserve and elevated ventricular filling pressures. Circulation 1985; 71: 234-243.
  6. Elliott P. M., Rosano G. M., Gill J. S. et al. Changes in coronary sinus pH during dipyridamole stress in patients with hypertrophic cardiomyopathy and chest pain. Heart 1996; 75: 179-183.
  7. Lund D. D. Myocardial morphology in spontaneously hypertensive and aortic-constricted rats. Am. J. Anat. 1978; 152: 141.
  8. Bonow R. O., Frederic T. M., Maron B. J. et al. Atrial systole and ventricular cardiomyopathy effect of verapamil. Am. J. Cardiol. 1983; 51: 1386.
  9. Picano E. The alternative ishemic cascade in coronary microvascular disease. Cardiologia 1999; 44 (9): 797-799.
  10. Nishimura K., Nosaka H., Kuribayashi T. et al. Another possible mechanism of angine in hypertrophic cardiomyopathy. Circulation 1983; 68: 111-162.
  11. Pichard A. D., Meller J. Septal perforator comression in idiopathic hypertrophic subaortic stenosis. Am. J. Cardiol. 1977; 40: 310.
  12. Hirasaki S., Nakamura Т., Kuribayashi T. et al. Abnormal course, abnormal flow, and systolic compression of the septal perforator associated with impaired myocardial perfusion in hypertrophic cardiomyopathy. Am. Heart J. 1999; 137 (1): 109-117.
  13. Iskandrin A. E., Nallamothu N., Neo J. et al. Nonatherosclerotic causes of myocadial ischemia. J. Nucl. Cardiol. 1996; 3 (5): 428-435.
  14. Okamoto F., Tanaka Т., Fujinara H. et al. CD 36 abnormality and impaired myocardial long chain fatty acid uptake in patients with hypertrophic cardiomyopathy. Jpn. Circ. J. 1998; 62 (7): 499-505.
  15. Matsuo S., Nakamura Y., Kuribayashi T. et al. Myocardial metabolic abnormalities in hypertrophic cardiomyopathy assessed by iodine-123-labeIed beta-methyl-branched fatty acid myocardial scintigraphy and its relation to exercise-induced ishemia. Ibid. (3): 167-172.
  16. Tamadura E., Kudon T., Matsumori A. et al. Impairment of BMIPP uptake preceds abnormalities in oxygen and glucose metabolism in hypertrophic cardiomyopathy. J. Nucl. Med. 1998; 39 (3): 390-396.
  17. Cjrbett J. R. Fatty acids for myocardial imaging. Semin. Nucl. Med. 1999; 29 (3): 237-258.
  18. Harjai K. J., Cheirif J., Murgo J. P. et al. Ischemia and atherosclerotic coronary artery disease in patients with hypertrophic cardiomyopathy: a review of incidence, pathophysiological mechanisms, clinical implications and management strategies. Coron. Artery Dis. 1996; 7 (3): 183-187.
  19. Pitcher D., Mainwright R., Maisey M. et al. Assessment of chest pain hypertrophic cardiomyopathy using exercise thaHium-201 myocardial scintygraphy. Br. Heart J. 1980; 44: 650-656.
  20. O'Gara P. Т., Bonow R. O., Maron B. J. et al. Myocardial perfusion abnormalities in patients with hypertrophic cardiomyopathy assessment with thallium-201 emission computed tomography. Circulation 1987; 76: 1214-1223.
  21. Cannon R. O., Dilsizian V., Epstein S. E. et al. Myocardial methabolic, hemodynamic, and electrocardiographic significance of reversible thallium-201 abnormalities hypertrophic cardiomyopathy. Ibid. 1991; 83: 1660-1667.
  22. Dilsizian V., Bonow R. O., Epstein S. E. et al. Myocardial ishemia detected by thallium scintigraphy is frequently related to cardiac arrest and syncope in young patients with hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 1993; 22: 796- 804.
  23. Yamada M., Elliott P. M., Kaski J. С. et al. Dipyridamole stress thallium-201 perfusion abnormalities in patients with hypertrophic cardiomyopathy. Relationship to clinical presentation and outcome. Eur. Heart J. 1998; 19: 500-507.
  24. Rubin K. A., Morrison J., Padnick M. B. et al. Idiopathic hypertrophic subaortic stenosis evaluation of anginal symptoms with thallium-201 myocardial imaging. Am. J. Cardiol. 1979; 44: 1040-1045.
  25. Von Dohlen T. W., Prisant L. M., Frank M. J. et al. Significance of positive or negative thallium-201 scintigraphy in hypertrophic cardiomyopathy. Ibid. 1989; 64: 498-503.
  26. Tamaki N., Morita K., Matsumori A. et al. Futura aspects of BMIPP. Int. J. Card. Imag. 1999; 15 (1): 79-89.
  27. Tamadura E., Tamaki N., Matsumori A. et al. BMIPP compared with PET metabolism. Ibid.: 61-69.
  28. Sugihara H., Taniguchi Y., Matsumori A. et al. Reverse redistribution of Tc-99m-tetrofosmin in exercise myocardial SPECT in patients with hypertrophic cardiomyopathy. Ann. Nucl Med. 1998; 12 (5): 287-292.
  29. Wieneke H., Zander С. Non-invasive characterization of cardiac microvascular disease by nuclear medicine using single-proton emission tomography. Herz 1999; 24 (7): 515-521.
  30. Hanrath P., Montz R., Mathey D. et al. Correlation between myocardial thallium-201 kinetics, myocardial lactate metabolism and coronary angiographic findings in hypertrophic cardiomyopathy. Z. Kardiol. 1980; 69: 353-359.
  31. Самойленко Л. Е. Перфузионная сцинтиграфия миокарда в клинической кардиологии: Автореф. дис. ... д-ра мед. наук. М.; 1998.
  32. Сергиенко В. Б. Однофотонная эмиссионная компьютерная томография. Опыт клинического применения: Автореф. дис. ... д-ра мед. наук. М.; 1984.
  33. Сергиенко В. Б., Свирщевский Е. Б. Радионуклидные методы исследования. В кн.: Чазов Е. И. (ред.) Болезни сердца и сосудов. М.: Медицина; 1992; т. 1: 429-442.
  34. Пирцхалаишвили Н. А. Внутрисердечная гемодинамика и состояние коронарного кровотока у больных гипертрофической кардиомиопатией: Дис. ... канд. мед. наук. М.; 1992.
  35. Дубов П. Б., Фофанова Т. В., Остроумов Е. Н. Миокардиальный резерв перфузии и гипертрофия миокарда у больных гипертоничексой болезнью и "немой" ишемией миокарда. Кардиология 1994; 6: 126-128.
  36. Сергиенко В, Б., Самойленко Л. Е., Ходарева Е. Н., Паша С. П. Перфузионная сцинтиграфия миокарда: взгляд через 25 лет. Практ. врач 1999; 15 (2): 20-24.
  37. Camici P., Chriatti С., Lorenzony R. et al. Coronary vasodilatation is impaired in both hypertrophied and nonhypertrophied myocardium of patients with hypertrophic cardiomyopathy: A study with nitrogen-13 ammonia and positron emission tomography. J. Am. Coll. Cardiol. 1991; 17: 879-886.
  38. Maddahi J., Abdulla A., Garia E. V. et al. Noninvasive identification of left main and triple vessel coronary artery disease: Improved accuracy using quantitative analysis of regional myocardium stress distribution and washout of thallium-201. Ibid. 1986; 7: 53-56.
  39. Hoffman J. I. Transmural myocardium perfusion. Progr Cardiovasc. Dis. 1987; 29: 429-464.
  40. Camici P. C., Cecchi F., Gistri R. et al. Dipyridamole induced subendocardial underperfusion in hypertrophic cardiomyopathy assessed by positron emission tomography. Coron. Artery Dis. 1991; 2: 837-841.

Copyright (c) 2003 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail:


© 2018-2021 "Consilium Medicum" Publishing house

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies